My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyclix Bio

Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Announces Publication in Nature Communications Highlighting Biomarkers of Response to CDK2 Inhibition
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Expands Board of Directors with Appointment of Norman E. Sharpless, MD
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Announces Abstract Accepted for Presentation at 2024 San Antonio Breast Cancer Symposium
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
From Incyclix Bio
Via GlobeNewswire
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
From Incyclix Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.